Mirati Therapeutics, Inc. (MRTX) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Net income	-740.9	-581.8	-357.9	-213.3	-98.4	-70.4	-83.1	-64.5
Depreciation and amortization [+]	2.9	1.8	0.6	0.2	0.2	0.2	0.2	0.2
Depreciation	2.9	1.8	0.6	0.2	0.2	0.2	0.2	0.2
Stock-based compensation	186.2	113.5	85.8	55.5	15.9	6.8	10.6	10.3
Change in working capital [+]	184.7	218.4	130.7	17.5	14.0	-4.6	5.5	4.7
Accounts receivable	-0.9
Inventories	-3.0
Other current assets	-4.6	-3.1	-4.2	-5.5	1.1	-3.4	0.3	0.3
Other	193.2	221.5	134.9	23.0	12.9	-1.2	5.3	4.4
Other operating activities	-203.5	-140.7	-130.8	-7.8	-1.7	3.3	-1.3	-1.3
Cash from operations	-570.6	-388.8	-271.5	-147.7	-70.1	-64.7	-68.0	-50.7

Capital expenditures	-4.9	-9.8	-4.4	-1.6	-0.1	-0.1	-0.2	-0.3
Purchases of property and equipment	-4.9	-9.8	-4.4	-1.6	-0.1	-0.1	-0.2	-0.3
Sales of short-term investments								54.5
Sales of short-term investments								54.5
Other cash from investing	230.7	-579.1	-135.5	-174.6	-145.6	-8.6	38.5	-105.0
Cash from investing	225.8	-588.9	-139.9	-176.1	-145.8	-8.7	38.3	-50.8

Issuance of common stock, net	155.0	474.7	1,203.6	327.8	130.7	153.5		143.3
Option exercises	9.9	28.0	45.9	8.5	9.7	5.0	2.4	0.6
Other cash from financing	21.8	58.5	93.0	18.7	19.9	10.2	5.0	1.6
Cash from financing	166.9	505.2	1,250.7	338.0	140.9	158.7	2.7	144.4

Free cash flow	-575.4	-398.6	-275.9	-149.3	-70.2	-64.8	-68.2	-51.0
Per share (diluted)	($10.23)	($7.68)	($6.13)	($3.98)	($2.27)	($2.56)	($3.45)	($3.02)